106 related articles for article (PubMed ID: 26983742)
1. Measuring Poliovirus Antigenicity by Surface Plasmon Resonance. Application for Potency Indicating Assays.
Westdijk J; van der Maas L; Ten Have R; Kersten G
Methods Mol Biol; 2016; 1387():299-323. PubMed ID: 26983742
[TBL] [Abstract][Full Text] [Related]
2. Methods for the Quality Control of Inactivated Poliovirus Vaccines.
Wilton T
Methods Mol Biol; 2016; 1387():279-97. PubMed ID: 26983741
[TBL] [Abstract][Full Text] [Related]
3. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
[TBL] [Abstract][Full Text] [Related]
4. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats.
Murakami K; Fujii Y; Someya Y
Vaccine; 2020 Apr; 38(17):3295-3299. PubMed ID: 32197923
[TBL] [Abstract][Full Text] [Related]
5. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
Kersten G; Hazendonk T; Beuvery C
Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
[TBL] [Abstract][Full Text] [Related]
6. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines.
Kouiavskaia D; Puligedda RD; Dessain SK; Chumakov K
J Virol Methods; 2020 Feb; 276():113785. PubMed ID: 31765719
[TBL] [Abstract][Full Text] [Related]
7. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.
Westdijk J; Brugmans D; Martin J; van't Oever A; Bakker WA; Levels L; Kersten G
Vaccine; 2011 Apr; 29(18):3390-7. PubMed ID: 21397718
[TBL] [Abstract][Full Text] [Related]
8. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
Liao G; Li R; Li C; Sun M; Li Y; Chu J; Jiang S; Li Q
J Infect Dis; 2012 Jan; 205(2):237-43. PubMed ID: 22158682
[TBL] [Abstract][Full Text] [Related]
10. [An ELISA system based on the specific class Y (IgY) antibodies from egg yolks for the quantitative determination of D-antigen in inactivated poliovirus vaccines].
Ivanov AP; Kozlov VG; Klebleeva TD; Ivanova OE; Kiktenko AV
Vopr Virusol; 2014; 59(6):39-42. PubMed ID: 25929036
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
Sawyer LA; McInnis J; Albrecht P
Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
[TBL] [Abstract][Full Text] [Related]
13. VaxArray immunoassay for the multiplexed quantification of poliovirus D-antigen.
Dawson ED; Taylor AW; Johnson JE; Hu T; McCormick C; Thomas KN; Gao RY; Wahid R; Mahmood K; Rowlen KL
J Immunol Methods; 2022 May; 504():113259. PubMed ID: 35314144
[TBL] [Abstract][Full Text] [Related]
14. Development of inactivated poliovirus vaccine derived from Sabin strains.
Simizu B; Abe S; Yamamoto H; Tano Y; Ota Y; Miyazawa M; Horie H; Satoh K; Wakabayashi K
Biologicals; 2006 Jun; 34(2):151-4. PubMed ID: 16679028
[TBL] [Abstract][Full Text] [Related]
15. Direct enzyme linked immunosorbent assay (ELISA) for quantification of poliomyelitis virus D-antigen.
Souvras M; Montagnon B; Fanget B; van Wezel AL; Hazendonk AG
Dev Biol Stand; 1980; 46():197-202. PubMed ID: 6244997
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
17. Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).
Rezapkin G; Dragunsky E; Chumakov K
Biologicals; 2005 Mar; 33(1):17-27. PubMed ID: 15713553
[TBL] [Abstract][Full Text] [Related]
18. [Effect of 2-phenoxyethanol on potency of Sabin inactivated poliomyelitis vaccine and its safety].
Bian CX; Jiang SD; Yang JY; Sun MB; Xie MX; Zhang XW; Liao GY; Li WD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):44-6. PubMed ID: 17429533
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
20. Rapid and accurate identification of poliovirus strains used for vaccine production.
Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
